Peter Martin is an Oncology physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 E 70th St
Starr 341
New York, NY 100219800
Telephone
646-962-2064Provider last certified this registry record 27 Jun 2023.
Clinical trials
- Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma
Sponsor: Weill Medical College of Cornell University
- KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Sponsor: Weill Medical College of Cornell University
- Treatment Of Chronic Anal Fissure
Sponsor: Bispebjerg Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20254 payments
- BeOne Medicines USA, Inc.Program year20252 payments
- AstraZeneca UK LimitedProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.2%Kinase inhibitor33.3%Brukinsa100%Part D<11 patientsBCL-2 Inhibitor22.9%Venclexta100%Part D<11 patientsAnti-infectives
43.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor43.8%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2011–2025 per NIH RePORTER. The latest:
- Expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens
New York University School of Medicine
FY2025$1,006,598R50CA305218 - Expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens
Weill Medical Coll of Cornell Univ
FY2025$1R50CA305218 - Fractionated, Dual-targeted radioimmunotherapy for follicular lymphoma
Weill Medical Coll of Cornell Univ
FY2011$340,155R21CA149978
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”